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ABSTRACT
Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are 
rare drug-related skin conditions that are potentially life-threatening with a 20–30% 
mortality rate. A severity-of-illness score specified for SJS and TEN, SCORTEN, was 
developed in 2000. Until now, no study of SCORTEN has been conducted in Asian 
with SJS or TEN. The goal of the present study is to evaluate the performance of 
SCORTEN in predicting in-hospital mortality in Taiwanese patient with SJS or TEN.
Methods A sample of 51 patients with the diagnosis of SJS or TEN was reviewed from 
the chart. Performance of the SCORTEN was assessed using logistic regression.
Results The hospital mortality rate predicted by the SCORTEN was similar to the 
observed mortality rate. The performance of SCORTEN was well on each of the first 5 
days of hospitalization, and best on the first day. There were two cases with active 
tuberculosis and five with diabetes mellitus among our eight deceased patients.
Conclusion The performance of SCORTEN is well in Taiwanese patients with SJS or TEN, 
especially on the first day of admission. The SCORTEN predicts a relatively accurate 
in-hospital mortality rate. We suggest that the SCORTEN should always be obtained 
during the first 24 hours, and can be repeated if the patient’s condition deteriorates 
quickly in the first 5 days. Pre-existing conditions, such as tuberculosis and pre-existing 
diabetes, may need more consideration in future studies.
Copyright © 2010, Taiwanese Dermatological Association. 
Published by Elsevier Taiwan LLC. All rights reserved.
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INTRODUCTION
Stevens-Johnson syndrome (SJS) and toxic epidermal necrol-
ysis (TEN) are rare drug-related skin conditions with epider-
mal detachment of the skin and mucosal erosion caused by 
sudden apoptosis of keratinocytes. They are potentially life-
threatening with a mortality rate of 20–30%.1 SJS and TEN 
are a spectrum of the same entity. SJS is defined as the total 
body surface area (BSA) of skin detachment lesser than 10%, 
while TEN is more than 30%, and in between is called 
SJS/TEN overlap.2
A severity-of-illness score specified for SJS or TEN, 
SCORTEN, was developed in 2000 in France. SCORTEN 
includes seven independent predictive factors, each stand 
an equal weight in the score, with scores ranging from 0 
to 7. The score is used to predict the mortality of a patient 
with SJS or TEN.1
SCORTEN was shown to accurately predict mortality in 
patients with TEN in the United States in 2004.3 It was also 
used as a mortality evaluating parameter for patients with 
SJS or TEN using intravenous immunoglobulin (IVIG).4 The 
performance of SCORTEN was also validated in 2006. The 
result revealed that the SCORTEN performance during 
the first 5 days of hospitalization was excellent, and best on 
the third day.5
It is important to have a predictable standard for the 
prognosis of SJS or TEN either for the clinicians or for the 
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patients and their families. The performance of SCORTEN 
has yet to be evaluated in Asia. The objective of the present 
study was to examine the performance of SCORTEN in pre-
dicting in-hospital mortality in Taiwanese patients with SJS 
or TEN. The performance of SCORTEN in the first 5 days of 
admission was analyzed.
Materials and methods
Patients and data collection
We included 51 patients with the diagnosis of SJS or TEN 
admitted to a medical center in Taipei city, from June 2001 
to June 2007. We retrospectively reviewed the chart of all 
patients. Among them, seven cases were ventilated during 
the first 5 days of admission and none of our patient was 
treated with IVIG. The outcome was in-hospital mortality.
SCORTEN includes seven independent predictive factors: 
(1) age greater than or equal to 40 years, (2) presence of 
malignancy, (3) skin detachment more than or equal to 10% 
of BSA, (4) heart rate greater than or equal to 120/min, (5) 
serum glucose level greater than 14.0 mmol/L (252 mg/dL), 
(6) serum bicarbonate level less than 20 mmol/L (20 mEq/L), 
and (7) serum urea nitrogen level greater than 9.6 mmol/L 
(27 mg/dL). Each factor stands an equal weight in the score, 
thus the score ranges from 0 to 7 (Table 1). We collected 
the raw data of all the variables. In the original study used to 
develop SCORTEN, some variables could not be measured 
in stable patients and were assumed to be within normal 
range.1 SCORTEN was calculated once daily on each day 
of the first 5 days of admission.
Statistical analysis
Data were analyzed using SAS 9.1.3 (SAS Institute, Cary, NC, 
USA) and SPSS 13.0 (SPSS Inc., Chicago, IL, USA) software. 
Descriptive data are summarized by number (percentages) 
or mean ± standard deviation. Patients who died during hos-
pitalization were compared with those who did not by using 
Fisher’s exact probability test for nominal variables, and un-
paired two-tailed t test for continuous variables. Differences 
were considered significant at p < 0.05.
The expected mortality rate predicted by the SCORTEN 
was calculated using the formula: P (death) = elogit/1 + elogit 
where logit = −4.448 + 1.237(SCORTEN).1 The standardized 
mortality ratio (standardized mortality ratio = ∑ observed 
deaths/∑ expected deaths) was used to determine whether 
there was a significant difference between observed and 
expected mortality on the first day.6
The SCORTEN from day 1 to day 5 were analyzed by 
using Friedman’s test and Dunn’s multiple comparisons 
test. The statistical performance of the successive SCORTEN 
from day 1 to 5 was assessed by using logistic regression. 
To evaluate model calibration, the correspondence between 
the predicted probabilities of mortality produced by the 
model and the actual in-hospital mortality was evaluated 
by Hosmer-Lemeshow statistic. To evaluate model discrimi-
nation, we used c statistics, which represents the area under 
the receiver-operating characteristic (ROC) curve. The c sta-
tistic values range from 0.5 (no greater predictive power 
than chance) to 1.0 (perfect prediction).7,8
RESULT
Patients
The database included 51 cases and 29 (56.86%) were 
males. Thirty-seven patients had SJS (72.55%), eight over-
lap SJS/TEN (15.69%), and six TEN (11.76%). The mean age 
was 62.71 ± 18.90 years. The mean admission delay was 
6.75 ± 7.62 days (range 0–30). There were eight deaths at 
discharge with a 16% mortality rate. The mortality rate in 
patients with SJS, overlap SJS/TEN, and TEN were 8.11%, 
37.5%, and 33.33%, respectively (Table 2). We used the 
same method as the original study in developing SCORTEN, 
if a variable was not measured for a stable patient, it was 
assumed to be within normal range.1 Every patient had a 
SCORTEN value. Among the 51 patients, there were 12 pa-
tients actually available for all seven SCORTEN factors (SJS 
6/37, overlap SJS/TEN 4/8, and TEN 2/6).
Mortality estimated by SCORTEN on the first day
Predicted mortality numbers were calculated by using 
the formula (P (death) = elogit/1 + elogit [logit = −4.448 +1.237
(SCORTEN)]) on the first day of hospitalization; the ob-
served mortality are presented in Table 3 and Figure 1. The 
observed mortality of our patients was not significantly dif-
ferent from the predicted mortality by using standardized 
mortality ratio analysis (standard mortality ratio, 1.12; 95% 
confidence interval, 0.48–2.21).6 There are 8 deaths among 
Table 1 SCORTEN: Seven independent prognostic factors of 
Stevens-Johnson syndrome/toxic epidermal necrolysis.*
Prognostic factor  Weight
Age (yr) ≥ 40 1
Malignancy Evolving cancer or 1
  hematologicalmalignancies
Body surface area of > 10% 1
 skin detachment
Heart rate ≥ 120/min 1
Serum glucose  > 14 mmol/L (252 mg/dL) 1
Serum bicarbonate < 20 mmol/L (20 mEq/L) 1
Serum urea nitrogen > 9.6 mmol/L (27 mg/dL) 1
*SCORTEN represents the summary of abnormal variables each with a 
weight of one among the seven independent prognostic factors.
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In order to find the differences of risk factors for death be-
tween Caucasian and Asian, we tried to identify other pos-
sible risk factors other than the seven factors in SCORTEN. 
In our data, the admission delay and the age of the patient 
showed significant difference between the patients who 
were alive and dead. Thus, we also analyzed the admission 
delay and attempted to determine a new cutting value of the 
age. However, these two variables became non-significant 
while using logistic regression.
Evolution of SCORTEN during admission
We also examined the evolution of SCORTEN over time 
with Friedman’s test and Dunn’s multiple comparisons test. 
However, there was no statistical difference between the 
SCORTEN through day 1 to day 5.
DISCUSSION
In our study, the mortality rate of patients diagnosed with SJS 
or TEN is 16%, which is lower than the 20–30% mortality 
rate reported in France and the United states.1,3 This may be 
because that the most of our cases were diagnosed with 
the 51 reviewed cases. Their clinical information is listed in 
Table 4.
The performance of SCORTEN
The successive SCORTEN values of the first 5 days of hos-
pitalization are demonstrated in Table 5. Calibration and 
discrimination of the SCORTEN were evaluated by logistic 
regression. Calibration of the SCORTEN evaluated by 
Hosmer-Lemeshow statistic8 indicated an excellent agree-
ment between the expected and observed numbers of deaths. 
Moreover, calibration was best on the first day of admission 
(p = 0.88). Discrimination of the SCORTEN was excellent 
and all c statistics were above 80% (Table 5).
Reanalysis of variables used to develop 
SCORTEN in our data
We collected all variables used to develop SCORTEN. We 
obtained a formula predicting the mortality with logistic 
regression with our own patient: P (death) = elogit/1 + elogit 
where logit = −4.2049 + 1.2125(SCORTEN). The result revealed 
similar findings between the predicted number of death cal-
culated by our formula and the original SCORTEN formula.
Table 2 Comparison of surviving and deceased patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
 Overall Alive Died p
No. of patients (%) 51 (100%) 43 (84%) 8 (16%)
Age (yr; mean ± SD) 62.71 ± 18.90 60.47 ± 19.44 74.75 ± 9.29 < .0001*
Men (%) 29 (56.9%) 23 (53.5%) 6 (75.0%) 0.4399†
Admission delay (d) 6.75 ± 7.62 6.95 ± 7.10  5.63 ± 10.50 < .0001*
SCORTEN 1.7 ± 1.1 1.5 ± 0.8 3.0 ± 1.6 < .0001*
Body surface area    0.0366†
  < 10% 37 34 (91.89%) 3 (8.11%)
  10–30% 8 5 (62.50%) 3 (37.50%)
  > 30% 6 4 (66.67%) 2 (33.33%)
*Unpaired t test; †Fisher's exact test.
Table 3 Observed and predicted mortality rate calculated by 
SCORTEN formula on the first day of hospitalization.
SCORTEN
 No. of  Predicted probability  Observed Predicted
 patients (%) of death* deaths (n) deaths
0 2 (3.9)  1.2% 0 0.024
1 24 (47.1)  3.9% 1 0.936
2 17 (33.3) 12.2% 3 2.074
3 4 (7.8) 32.4% 1 1.296
4 3 (5.9) 62.2% 2 1.866
5 0 85.0% 0 0
6 1 (2.0) 95.1% 1 0.951
7 0 98.5% 0 0
All 51 (100.0)  8 7.147
*Values predicted by the SCORTEN with the formula P (death) = elogit/
1 + elogit where logit = −4.448 + 1.237(SCORTEN).
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Figure 1 Observed and predicted in-hospital mortality as calculated 
by SCORTEN formula on the first day of hospitalization. SCORTEN 
formula: P (death) = elogit/1 + elogit, logit = − 4.448 +1.237(SCORTEN).
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SJS(37/51), which has lesser skin detachment and lower 
mortality rate (< 10%) compared with the mortality rate 
(30 to 50%) of SJS/TEN overlap and TEN.
The performance of SCORTEN on the first day of admis-
sion as demonstrated in Table 3 revealed good correspond-
ence between the observed and predicted mortality, meaning 
that the SCORTEN is suited in predicting the mortality of 
SJS and TEN in Taiwanese. We also analyzed the perform-
ance of SCORTEN in the first 5 days of admission. The high-
est correlation was on the first day of admission. A previous 
study5 showed an excellent agreement between the ob-
served and expected numbers of death during the first 
5 days of admission, with the highest agreement on the third 
day.5 Their data suggested that SCORTEN might evolve over 
time since the disease did progress significantly in the first 
few days. The SCORTEN score might underestimate the mor-
tality on day 1 and day 2 and overestimate the mortality on 
day 4 and day 5.5 However, our data showed high p value 
of the Hosmer-Lemeshow statistic on each of the first 5 days 
of admission, especially on the first day. In our opinion, the 
original SCORTEN model was established by using data ob-
tained on the first day. As a result, it should have the best 
agreement on the first day. We suggested that, in Taiwanese 
patients with SJS or TEN, SCORTEN should always be ob-
tained during the first 24 hours, and could be repeated if the 
patient’s condition deteriorated quickly in the first 5 days.
We also obtained our formula for predicting the mortal-
ity with logistic regression within our patient. We compared 
the predicted mortality with the mortality calculated by the 
original SCORTEN formula. The result revealed similar find-
ings between the observed number of deaths and predicted 
number of deaths calculated by the original formula and 
our formula. The above results indicated that there is no 
difference in the SCORTEN-predicted mortality between 
Caucasian and Taiwanese.
The SCORTEN could be used to evaluate the effective-
ness of new therapeutic agents. The predicted mortality rate 
could also be modified when effective treatment becomes 
available. The performance of the SCORTEN has been ex-
amined at a burn center in Canada, with results suggesting 
SCORTEN as an accurate scoring system.9 In another study 
in the United States,3 only 24 cases of TEN were included. 
The difference between the actual and predicted mortality 
found in that study was not statistically significant.3 The 
same author had used SCORTEN to evaluate the mortality 
of 16 patients treated with IVIG.4 The result revealed that 
the mortality of patients treated with IVIG significantly de-
creased in comparison with the SCORTEN-predicted mor-
tality rate. Another study10 in 2006 claimed that SCORTEN 
overestimates mortality. In that study, 109 patients diagnosed 
with TEN were enrolled. They were admitted to the burn 
intensive care unit and thus received higher standardized 
treatment than did the ordinary ward, including routine 
IVIG administration. The lower mortality rate in this study10 T
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may be attributed to the standardized protocol, including 
routine administration of IVIG. However, it remains contro-
versial whether IVIG was an effective treatment of SJS or 
TEN.4,11–16
There are several severity-of-illness score being used to 
evaluate the mortality rate for critically ill patients but none 
are developed specifically for the patients of SJS and TEN. 
Acute Physiology and Chronic Health Evaluation II (APACHE 
II) score, one of the most commonly used score, has been 
used in patients with TEN for evaluating the therapeutic in-
terventions. Research was only able to show that higher 
APACHE II score correlated with increasing mortality with-
out validating its discriminatory power in predicting mor-
tality.17,18 The risk factors of scores proposed for burns are 
usually related to inhalation injury in addition to age and 
burn area.19 With respect to Simplified Acute Physiology 
Score II (SAPS II), the original development sample ex-
cluded burns patients and TEN patients.1 In fact, the dis-
criminatory powers of SAPS II and the burn score proposed 
by Ryan et al19 were not satisfactory given that the area 
under the ROC curve was 0.72 in the former and 0.75 in 
the latter.
There were eight deaths in our study and seven of them 
developed SJS or TEN after admission. They were all com-
plicated with sepsis and antibiotics were suspected as the 
causative agents of SJS and TEN. If there was no other suitable 
antibiotic that could treat the infection without exacerbating 
the skin condition, the patient would have less chance to 
survive.
There were two cases with active tuberculosis and five 
with diabetes mellitus in our deceased patients. It has been 
proposed that tuberculosis and pre-existing diabetes should 
be taken into account.20 Since pre-existing tuberculosis could 
be considered as a kind of pulmonary condition that could be 
reflected on serum bicarbonate, and pre-existing diabetes 
could be reflected on serum glucose level, these pre-existing 
conditions may require more consideration in future studies.
Investigators have proposed that SCORTEN might not 
reflect the effect of respiratory involvement such as bron-
chial necrosis21 since it did not include ventilated patients 
in the first 5 days of admission in the original study.1 In our 
opinion, the factor serum bicarbonate level could be taken 
as a predicting factor for poor oxygenation. In our study, 
there were seven cases ventilated during the first 5 days of 
admission. The good performance of predicted mortality 
rate was not affected.
It has been argued that SCORTEN should be modified, 
and that BSA involvement and age should be weighted more 
in calculations.20 The main problem is related to the statisti-
cal method. We tried to analyze our patient data with Cox’s 
regression model and tried to grade the value of each vari-
able. However, we also encountered similar problems dis-
cussed in the original article proposing the SCORTEN, which 
enrolled 165 patients.1 Given the low incidence rate of SJS 
and TEN, the sample size and the difficulties in collecting 
all the variables did not allow us to have a satisfactory re-
sult using the more suitable statistical method such as sur-
vival analysis.1 Another study suggesting modification of 
SCORTEN only enrolled 10 patients.20 Logistic regression 
might not be the best method in this type of study, but it is 
a relatively acceptable and feasible way for providing 
useful information. Thus, we applied logistic regression to 
examine our variables.
The admission delay and the age of the patient showed 
significant differences between the survivors and the de-
ceased in our raw data analysis. However after analyzing 
the admission delay using the logistic regression model, no 
significant differences emerged. In a previous study,5 the ad-
mission delay was not different between deceased patients 
and survivors; this result was probably attributed to earlier 
Table 5 Values and performance of the SCORTEN on each of the first 5 days of hospitalization.
 Day 1 Day 2 Day 3 Day 4 Day 5
SCORTEN, mean ± SD 1.73 ± 1.10 1.75 ± 1.04 1.90 ± 1.19 1.94 ± 1.26 1.84 ± 1.17
Maximal value 6 5 5 5 5
SCORTEN (%)
 0 2 (3.92) 2 (3.92) 3 (5.88) 3 (5.88) 3 (5.88)
 1 24 (47.06) 23 (45.10) 20 (39.22) 20 (39.22) 22 (43.14)
 2 17 (33.33) 17 (33.33) 15 (29.41) 14 (27.45) 13 (25.49)
 3 4 (7.84) 5 (9.80) 6 (11.76) 7 (13.73) 7 (13.73)
 4 3 (5.88) 3 (5.88) 6 (11.76) 6 (11.76) 5 (9.80)
 5 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
 6 1 (1.96) 1 (1.96) 1 (1.96) 1 (1.96) 1 (1.96)
SCORTEN, OR (95% CI) 3.36 (1.42−7.96) 5.16 (1.82−14.63) 4.94 (1.86−13.08) 4.67 (1.75−12.52) 5.89 (1.98−17.52)
p (calibration)* 0.88 0.73 0.52 0.65 0.79
c statistic†   0.808   0.887   0.910   0.904   0.922
*As determined by Hosmer-Lemeshow statistic in logistic regression, it indicates the correspondence between the predicted and the actual in-hospital 
deaths; †c statistic represents the area under the receiver-operating characteristic curve, which ranges from 0.5 (no greater predictive power than chance) 
to 1.0 (perfect prediction).
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of the probability of death from burn injuries. N Engl J Med 
1998;338:362–6.
20. Vaishampayan SS, Das AL, Verma R. SCORTEN: does it need 
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21. Hague JS, Goulding JM, Long TM, et al. Respiratory involvement 
in toxic epidermal necrolysis portends a poor prognosis that may 
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admission of the severe cases.5 We tried to determine a cut-
ting value for age, which had been a factor in SCORTEN, in 
our study population. However, due to the small sample 
size and possible selection bias for being a veteran hospital, 
where the patient group was older than the general popula-
tion of patients from other hospitals, the factor ‘age’ revealed 
no statistic significance using logistic regression. A larger 
sample size is needed to collect more usable information 
for the variables. At present, we believe that SCORTEN is a 
better scoring system than other severity evaluating system 
for patients of SJS or TEN.
In conclusion, SCORTEN performed well in Taiwanese 
patients with SJS or TEN, especially for the first day of 
admission. The SCORTEN predicts a relatively accurate 
mortality. We suggest that SCORTEN should always be ob-
tained during the first 24 hours, and could be repeated if the 
patient’s condition deteriorated quickly in the first 5 days.
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